A Phase 4 interventional study of Alfentanil and Placebos in Blood Pressure and Electroconvulsive Therapy, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.
Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis by anesthesiologists on other surgeries so this is not a new indication.
Electroconvulsive therapy is associated with brief hemodynamic alterations that in some patients may be well outside the range of normalcy and potentially dangerous to the patient (Duma A, et al). This cardiovascular response is caused by activation of the autonomic nervous system and consists of an initial parasympathetic response rapidly followed by sympathetically mediated tachycardia and hypertension. The ultra-short acting synthetic opioid alfentanil has a rapid onset and duration of action that mirrors the duration of hemodynamic perturbation associated with Electroconvulsive Therapy (ECT) while having minimal or no effect on the duration or quality of the seizure. This drug may be effective in blunting the hemodynamic perturbations associated with ECT with a minimal amount of side effects.
Wake Forest University Health Sciences is the lead sponsor of 1,352 studies on the registry; 201 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Alfentanil
Drug: Placebos
Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Systolic Blood Pressure Change
comparison of Systolic blood pressure changes alfentanil vs placebo
Time frame: Baseline and up to 90 minutes
Diastolic Blood Pressure Change
comparison of diastolic blood pressure change alfentanil vs placebo
Time frame: Baseline and up to 90 minutes
Heart Rate
comparison of heart rate change alfentanil vs placebo
Time frame: Baseline and up to 15 seconds
Heart Rate
comparison of heart rate change alfentanil vs placebo
Time frame: Baseline and up to 30 seconds
Heart Rate
comparison of heart rate change alfentanil vs placebo
Time frame: 90 minutes
Maximum Heart Rate
comparison of heart rate change alfentanil vs placebo
Time frame: Baseline and up to 90 minutes
Minimum Heart Rate
comparison of heart rate change alfentanil vs placebo
Time frame: Baseline and up to 90 minutes
Doses of Antihypertensive Medication
comparison of amounts of medications needed to treat blood pressure between the 2 groups
Time frame: 90 minutes
Time to Return of Spontaneous Ventilation
time to return to breathing without assistance
Time frame: up to 90 minutes
Total Time Subject Spent In-Room
comparison of amounts time spent in-room between the 2 groups
Time frame: up to 90 minutes
Severity of Headache in the Post Anesthesia Care Unit
comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst
Time frame: up to 90 minutes
Satisfaction With the Anesthetic Post-procedure
comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst
Time frame: up to 90 minutes
| Milestone | Alfentanil Then Placebo | Placebo Then Afentanil |
|---|---|---|
| Started | 49 | 50 |
| Completed | 46 | 47 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Milestone | Alfentanil Then Placebo | Placebo Then Afentanil |
|---|---|---|
| Started | 46 | 47 |
| Completed | 43 | 44 |
| Not completed | 3 | 3 |
| Withdrew: Exclusion criteria | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
comparison of Systolic blood pressure changes alfentanil vs placebo
| mmHg | Alfentanil | Placebo |
|---|---|---|
| Systolic Blood Pressure Change | 22.011 ± 36.968 | 38.908 ± 33.50864 |
comparison of diastolic blood pressure change alfentanil vs placebo
| mmHg | Alfentanil | Placebo |
|---|---|---|
| Diastolic Blood Pressure Change | 15.26 ± 23.3848507043 | 23.34 ± 24.40 |
comparison of heart rate change alfentanil vs placebo
| Beats per Minute | Alfentanil | Placebo |
|---|---|---|
| Heart Rate | 26.00 ± 19.823 | 28.197674418604 ± 21.486 |
comparison of heart rate change alfentanil vs placebo
| Beats per Minute | Alfentanil | Placebo |
|---|---|---|
| Heart Rate | 37.48 ± 25.46 | 36.93 ± 25.46 |
comparison of heart rate change alfentanil vs placebo
No measurements were reported for this outcome.
comparison of heart rate change alfentanil vs placebo
| Beats per Minute | Alfentanil | Placebo |
|---|---|---|
| Maximum Heart Rate | 44.33 ± 24.274 | 49.66 ± 26.629 |
comparison of heart rate change alfentanil vs placebo
| Beats per Minute | Alfentanil | Placebo |
|---|---|---|
| Minimum Heart Rate | 12.74 ± 14.674 | 7.08 ± 19.221 |
comparison of amounts of medications needed to treat blood pressure between the 2 groups
No measurements were reported for this outcome.
time to return to breathing without assistance
| Minutes | Alfentanil | Placebo |
|---|---|---|
| Time to Return of Spontaneous Ventilation | 8.17 ± 2.483 | 7.25 ± 1.869 |
comparison of amounts time spent in-room between the 2 groups
| Minutes | Alfentanil | Placebo |
|---|---|---|
| Total Time Subject Spent In-Room | 17.51 ± 4.640 | 16.43 ± 3.940 |
comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst
| score on a scale | Alfentanil | Placebo |
|---|---|---|
| Severity of Headache in the Post Anesthesia Care Unit | 2 ± 2.887 | 2.467 ± 3.038 |
comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst
| score on a scale | Alfentanil | Placebo |
|---|---|---|
| Satisfaction With the Anesthetic Post-procedure | 8 ± 2.449 | 8.033 ± 2.505 |
Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alfentanil | 1/87 (1.1%) | 1/87 (1.1%) | 0/87 (0%) |
| Placebo | 1/87 (1.1%) | 1/87 (1.1%) | 0/87 (0%) |
| Event | Alfentanil | Placebo |
|---|---|---|
| SuicideSocial circumstances | 1/87 | 1/87 |
| Event | Alfentanil | Placebo |
|---|---|---|
| SuicideSocial circumstances | 0/87 | 0/87 |
| Age, Continuous(years) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| Mean | 51.34 ± 17.10 | 51.94 ± 13.96 | 51.621 ± 15.57 |
| Sex: Female, Male(Participants) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| Female | 35 | 32 | 67 |
| Male | 14 | 18 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 48 | 48 | 96 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 48 | 46 | 94 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| United States | 49 | 50 | 99 |
| Height (cm)(Centimeters) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| Mean | 167.57 ± 11.31 | 167.59 ± 10.25 | 167.58 ± 10.67 |
| Weight (kg)(kilograms) | Alfentanil Then Placebo Arm 1 | Placebo Then Alfentanil Arm 2 | Total |
|---|---|---|---|
| Mean | 86.28 ± 31.57 | 85.156 ± 27.33 | 85.405 ± 30.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Feb 2020, 20 months.
Results were first posted in Jul 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alfentanil
Wake Forest University Health Sciences →